Genomic Health, Inc. (GHDX) stock falls, “Sell” rating reaffirmed by Barclays PLC Analysts

Genomic Health, Inc. (NASDAQ: GHDX) shares fell in early trading today on lower trade volume than normal after a number of analysts weighed in on the investing value of the stock and reiterated thier respective ratings.

Meanwhile, U.S. stocks edged lower Monday, with major indexes retreating from record levels.

The Dow Jones Industrial Average DJIA, -0.31% fell 48 points, or 0.2%, to 19,916, while the S&P 500 index SPX, -0.29% lost 5 points to 2,272, a drop of 0.2%. The Nasdaq Composite Index COMP, -0.03% rose 4 points to 5,529, a gain of about 0.1%.

Barclays PLC analysts reiterated its Sell rating on Genomic Health, Inc. (NASDAQ: GHDX) in a note to investors, making it one of the more closely watched stocks on Wall Street. With a rating of Sell on the shares, the company has a 52-week high of $34.18. A number of other analysts have spoken on the company recently, and the company has secured a consensus one-year price target of $32.65, higher than the opening price of $29.52. Share prices sometimes get a bounce to the upside when analysts reiterate coverage.

Shares of Genomic Health, Inc. (NASDAQ: GHDX) opened at $29.52 yesterday trading between $29.12 and $29.52, and last traded at $29.13, which represents a dip of $0.29 compared to the previous closing price.

Genomic Health, Inc. (NASDAQ: GHDX) now has a market cap of 975.24M.

Genomic Health, Inc. (NASDAQ: GHDX) Average Daily Trading Volume

14,507 shares crossed the trading desk yesterday, 116 percent lower than the norm, out of a total float 16,263,000. lower than normal. Look for trading volume to pick up in the coming days as investors often use swings in trading volume to identify heavy volume accumulation or distribution by institutional investors.

While increased trading for short periods will not mean much will not mean much, however, a trend of heavy trading volume on the buy side over a period of days or weeks sends a positive signal to market traders that institutions may be moving in, so institutional sponsorship is very important.

Institutional sponsorship is defined by ownership of a stock by mutual funds, banks, pension funds and other large institutions.

These professional investors have teams of analysts that investigate thousands of stocks. So watching their interests is a good way to ensure you are buying the right stocks.

Genomic Health, Inc. (NASDAQ: GHDX) Moving Averages

A moving average can also act as support or resistance. In an uptrend a 50-day, 100-day or 200-day moving average may act as a support level, as shown in the figure below.

This is because the average acts like a floor (support), so the price bounces up off of it.

In a downtrend a moving average may act as resistance; like a ceiling, the price hits it and then starts to drop again.

By tracking the activity of these professional investors—and the moving averages they affect—it allows for traders to make more effective decisions on trades.

With that in mind, Genomic Health, Inc. (NASDAQ: GHDX) now has a 50-day MA of $30.58 and 200-day MA of $28.99. It has traded in a 52-week range between $22.00 – 34.18 and today’s last price is 14.77%% lower than the 52 week high of $34.18.

Indeed, earnings growth is among the most important things to look at in regards to stock investing and, accordingly, investors seek companies that have been successful at growing their earnings by at least 25% over 3 consecutive years.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Leave a Reply

Your email address will not be published. Required fields are marked *